Shalitin C, Epelbaum R, Moskovitz B, Segal R, Valansi C, Mekori T, Lerner M
RAMBAM MED CTR,DEPT ONCOL,HAIFA,ISRAEL. RAMBAM MED CTR,DEPT UROL,HAIFA,ISRAEL.
Int J Oncol. 1992 Jun;1(1):107-12. doi: 10.3892/ijo.1.1.107.
A novel 21 kDa protein (p21) was detected in sera of patients with urogenital tumors by ELISA, using rabbit polyclonal antibodies generated against the p21 polypeptide. Eight out of 11 patients (72%) exhibited a 2-5 fold increase in pre-treatment p21 serum levels as compared with 20 healthy individuals. A decrease of p21 levels was observed in 6 out of 8 patients in which a regression of the disease was shown post-treatment. An increase or no change in p21 levels was observed in 3 patients with no change or progression of the disease. The ELISA described herein may be useful for clinical monitoring of patients with urogenital tumors, some of which have no available tumor marker.
使用针对p21多肽产生的兔多克隆抗体，通过酶联免疫吸附测定（ELISA）在泌尿生殖系统肿瘤患者的血清中检测到一种新的21 kDa蛋白（p21）。11名患者中有8名（72%）在治疗前的p21血清水平与20名健康个体相比升高了2至5倍。在8名治疗后疾病出现消退的患者中，有6名观察到p21水平下降。3名疾病无变化或进展的患者中，观察到p21水平升高或无变化。本文所述的ELISA可能有助于对泌尿生殖系统肿瘤患者进行临床监测，其中一些患者没有可用的肿瘤标志物。
